Barrett’s esophagus (BE) is caused by gastroesophageal reflux disease (GERD) and harbors an increased risk for esophageal cancer [
1‐
3]. Via a sequence involving low- (LGD) and high-grade dysplasia (HGD), esophageal adenocarcinoma may develop (annual cancer risk: 0.1–0.7 %) [
4,
5]. Indefinite for dysplasia (ID) defines a condition where the presence or absence of dysplasia cannot be accurately assessed, due to inflammatory changes in the mucosa. Re-endoscopy and biopsy sampling is recommended after a 3–4 weeks course of double dose proton pump inhibitor (PPI) therapy p.o. (i.e. 2 × 40 mg PPI). Diagnosis of BE is established if biopsies obtained from endoscopically visible segments, tongues or islands of columnar lined esophagus (CLE) contain goblet cells ± LGD, HGD or cancer [
6]. …